Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 30 min 37 sec ago

Stryker Announces Definitive Agreement to Acquire Assets of Small Bone Innovations, Inc.

Mon, 06/30/2014 - 15:47
Kalamazoo, Michigan - June 30, 2014 -- (Healthcare Sales & Marketing Network) -- Stryker Corporation (SYK) announced today a definitive agreement to acquire assets of Small Bone Innovations, Inc. ("SBi") in an all cash transaction for up to $375 ...
Devices, Orthopaedic, Acquisitions
Stryker, Small Bone Innovations, total ankle replacement

Benvenue Medical Expands Senior Management Team

Mon, 06/30/2014 - 15:43
Jeffrey Jones Joins as Chief Operating Officer SANTA CLARA, Calif., June 30, 2014 -- (Healthcare Sales & Marketing Network) -- Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, today announced that Jeffrey Jones has ...
Devices, Orthopaedic, Neurosurgery, Personnel
Benvenue Medical, VCF Treatment System

Stryker Corporation To Acquire Small Bone Innovations

Mon, 06/30/2014 - 15:40
MORRISVILLE, Pa.--(Healthcare Sales & Marketing Network)--Small Bone Innovations, Inc. (SBi) today announced that Stryker Corporation (SYK) will acquire substantially all the assets of SBi in an all cash transaction for up to $375 million. The transacti...
Devices, Orthopaedic, Mergers & Acquisitions
Small Bone Innovations, Stryker, Total Ankle

Allergan Announces RandD Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET

Mon, 06/30/2014 - 15:37
Announces Positive Phase 2 Data for Abicipar Pegol (Anti-VEGF DARPin®) and Advances to Phase 3 Trials Advances Bimatoprost Sustained-Release Implant for Glaucoma to Phase 3 Trials Receives FDA Approval for OZURDEX® (dexamethasone intravitreal...
Biopharmaceuticals, Ophthalmology, FDA
Allergan, OZURDEX, dexamethasone, intravitreal implant, diabetic macular edema

Cidara Therapeutics Completes $32 Million Series A Financing

Mon, 06/30/2014 - 13:33
Veteran team to apply novel, small molecule immunotherapy platform to treat severe fungal infections in immune compromised patients SAN DIEGO, Calif.--(Healthcare Sales & Marketing Network)--Cidara Therapeutics, Inc., a privately held biopharmaceutical ...
Biopharmaceuticals, Personnel
Cidara Therapeutics

Baxano Surgical Announces First Clinical Use of the Avance MIS Pedicle Screw System

Mon, 06/30/2014 - 13:27
RALEIGH, N.C., June 30, 2014 -- (Healthcare Sales & Marketing Network) -- Baxano Surgical, Inc. (BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine...
Devices, Neurosurgery, Orthopaedic
Baxano Surgical, Avance MIS, Pedicle Screw, spine surgery

Titan Medical Inc. Corporate Update

Mon, 06/30/2014 - 13:23
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Titan Medical Inc. (the "Company") (TSX VENTURE:TMD) (TITXF) announced today that Mr. Joe Talarico, Senior Vice President Business Development has resigned his position with the Company. ...
Devices, Surgery, Personnel
Titan Medical, robotic surgery

InSightec Announces a New Series D Funding of $50 Million to Accelerate Market Development of MR-Guided Focused Ultrasound Noninvasive Treatments

Mon, 06/30/2014 - 13:15
TIRAT CARMEL, Israel, June 30, 2014 -- (Healthcare Sales & Marketing Network) -- InSightec, the global leader and pioneer in MR-guided focused ultrasound (MRgFUS) therapy for the non-invasive treatment of tumors, announced today that it is raising $50 mil...
Devices, Venture Capital
InSightec, MR-guided focused ultrasound, MRgFUS

Flamel Technologies Announces FDA Approval of VAZCULEP

Mon, 06/30/2014 - 13:10
LYON, FRANCE--(Healthcare Sales & Marketing Network) - Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for VAZCULEP™ (phenylephrine hydrochloride). VA...
Biopharmaceuticals, FDA
Flamel Technologies, VAZCULEP, phenylephrine hydrochloride

Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer

Mon, 06/30/2014 - 13:06
CAMBRIDGE, MA--(Healthcare Sales & Marketing Network) - Proteostasis Therapeutics, Inc., a developer of novel therapeutics regulating protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced the appoi...
Biopharmaceuticals, Personnel
Proteostasis Therapeutics

CHMP Recommends EU Approval of VIZAMYL(TM) (Flutemetamol F18 Injection) for PET Imaging of Beta Amyloid Plaque

Mon, 06/30/2014 - 12:59
PET Imaging Agent Receives Positive Opinion CHALFONT ST. GILES, England--(Healthcare Sales & Marketing Network)--GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Hu...
Biopharmaceuticals, Radiology, Neurology, Regulatory
GE Healthcare, VIZAMYL, Flutemetamol F18, PET , Alzheimer’s disease, imaging

EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union

Fri, 06/27/2014 - 13:48
TARRYTOWN, N.Y., June 27, 2014 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products f...
Biopharmaceuticals, Ophthalmology, Regulatory
Regeneron Pharmaceuticals, EYLEA, aflibercept, diabetic macular edema

Vertex Receives European CHMP Positive Opinion for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations

Fri, 06/27/2014 - 13:42
In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D gating mutations EYSINS, Switzerland--(Healthcare Sales & Marke...
Biopharmaceuticals, Regulatory
Vertex Pharmaceuticals, KALYDECO, ivacaftor, cystic fibrosis

Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza(R) (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

Fri, 06/27/2014 - 13:36
Daklinza in combination with other agents would offer a potential cure for HCV patients with high unmet needs who urgently require treatment, if approved PRINCETON, N.J.--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) today a...
Biopharmaceuticals, Regulatory
Bristol-Myers Squibb, Daklinza, daclatasvir, hepatitis C

Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE

Fri, 06/27/2014 - 13:30
PRINCETON, N.J. & NEW YORK--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Biopharmaceuticals, Regulatory
Bristol-Myers Squibb, Pfizer, Eliquis, apixaban, DVT , pulmonary embolism

Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

Fri, 06/27/2014 - 13:22
CARMIEL, Israel, June 27, 2014 -- (Healthcare Sales & Marketing Network) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (PLX.TA), announced today that new clinical data on ELELYSOTM (taliglucerase alfa) will be presented at the European Working Group on ...
Biopharmaceuticals
Protalix BioTherapeutics, ELELYSO, taliglucerase alfa, Gaucher Disease

Dune Medical Devices Raises $21 Million in Funding

Thu, 06/26/2014 - 16:26
Two-stage Financing will Support Expansion of Commercial Rollout of MarginProbe CAESAREA, Israel, June 26, 2014 -- (Healthcare Sales & Marketing Network) -- Dune Medical Devices, announced today that it has successfully completed the first of a two sta...
Devices, Diagnostics, Oncology, Venture Capital
Dune Medical Devices, MarginProbe

Esperion Therapeutics Announces the Appointment of Gilbert S. Omenn, M.D., Ph.D. to Board of Directors

Thu, 06/26/2014 - 16:22
ANN ARBOR, Mich.--(Healthcare Sales & Marketing Network)--Esperion Therapeutics, Inc. (ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering th...
Biopharmaceuticals, Cardiology, Personnel
Esperion Therapeutics, hypercholesterolemia

Ivenix Designs Next-Generation Infusion Management System to Transform Infusion Pump Market

Thu, 06/26/2014 - 16:18
New Infusion Platform Combines Simple and Intuitive User Interface with State-of-the Art Information Technology and Adaptive Pumping System that Measures Flow to Improve Patient Safety and Workflow Efficiency AMESBURY, Mass., June 26, 2014 -- (Healthcar...
Devices, Drug Delivery
Ivenix, infusion pump

Tris Pharma Expands RandD Team with addition of Chief Medical Officer and Vice President of Regulatory Affairs

Thu, 06/26/2014 - 16:13
MONMOUTH JUNCTION, N.J., June 26, 2014 -- (Healthcare Sales & Marketing Network) -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative technology-based products announced two key additions to its' executive team: Sally A. Be...
Biopharmaceuticals, Personnel
Tris Pharma

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong